Coya Therapeutics (COYA) announced that dosing of ALS patients in the company’s ALSTARS trial of COYA 302 has commenced.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COYA:
- Coya Therapeutics: Strong Financial Position and Upcoming Catalysts Support Buy Rating
- Coya Therapeutics Reports Q3 2025 Financial Results
- Coya Therapeutics reports Q3 EPS (13c), consensus (30c)
- Coya Therapeutics price target raised to $17 from $16 at Lake Street
- Coya Therapeutics announces results from COYA 303 in vivo animal study